Bedaquiline susceptibility test for totally drug-resistant tuberculosis Mycobacterium tuberculosis

This study aimed to provide information that bedaquilline is significantly effective for treatment of totally drug resistant (TDR) Mycobacterium tuberculosis that shows resistant to all first- and second-line drugs-using an innovative disc agarose channel (DAC) system. Time-lapse images of single ba...

Full description

Saved in:
Bibliographic Details
Published in:The journal of microbiology 2017, 55(6), , pp.483-487
Main Authors: Jang, Ji-Chan, Jung, Yong-Gyun, Choi, Jungil, Jung, Hyunju, Ryoo, Sungweon
Format: Article
Language:English
Subjects:
Agarose
Antitubercular Agents - therapeutic use
Bacteria
Biomedical and Life Sciences
Cell culture
Cells
Diarylquinolines - therapeutic use
Drug resistance
Drugs
Extensively Drug-Resistant Tuberculosis - drug therapy
Growth
Humans
Image processing
Life Sciences
Microbial Pathogenesis and Host-Microbe Interaction
Microbial Sensitivity Tests
Microbiological strains
Microbiology
Minimum inhibitory concentration
Mycobacterium tuberculosis - drug effects
Regulatory agencies
Solutions
Time-Lapse Imaging
Tuberculosis
Tuberculosis, Pulmonary - drug therapy
생물학
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:This study aimed to provide information that bedaquilline is significantly effective for treatment of totally drug resistant (TDR) Mycobacterium tuberculosis that shows resistant to all first- and second-line drugs-using an innovative disc agarose channel (DAC) system. Time-lapse images of single bacterial cells under culture conditions with different concentrations of bedaquiline were analysed by image processing software to determine minimum inhibitory concentrations (MICs). Bedaquiline inhibited the growth of TDR M. tuberculosis strains, with MIC values ranging from 0.125 to 0.5 mg/L. The results of the present study demonstrate that bedaquiline, newly approved by the United States Food and Drug Administration (FDA), may offer therapeutic solutions for TDR-TB.
ISSN:1225-8873
1976-3794
DOI:10.1007/s12275-017-6630-1